Living With Thalassemia Major: A Day-to-Day Guide

 Most articles about thalassemia major talk about it as a condition — what causes it, how it's classified, what the long-term outlook looks like. Fewer talk about what a Tuesday actually looks like when you're managing it. This is meant for that gap: for patients living with it day to day, and for the parents, partners, and caregivers building a life around it alongside them.

What "Living With Thalassemia Major" Actually Means, Day to Day

Thalassemia major — sometimes called Cooley's anemia — is the most severe form of beta-thalassemia, and it requires ongoing medical management rather than a one-time treatment. In practical terms, that means two things shape daily life more than anything else: a transfusion schedule, and the chelation routine that goes with it.

Blood Transfusions: Building a Life Around a Schedule

For most people with thalassemia major, regular blood transfusions aren't optional — they're what keeps hemoglobin at a level that allows for normal energy, growth, and organ function. Transfusions are typically needed every two to four weeks, and for many people, that becomes as routine as any other recurring medical appointment, if not quite as simple. Clinical guidance for patients recommends sticking to one transfusion center where possible, since consistency in blood matching, staff familiarity, and record-keeping all make the process smoother over time.

The transfusion itself usually takes a few hours, which means the day of a transfusion often gets built around it — work or school schedules shift, and many patients describe learning to plan the rest of their week around how they'll feel before and after.

Iron Chelation: The Routine Behind the Routine

Here's the part that surprises people who are new to thalassemia major: the transfusions themselves aren't the only ongoing commitment. Every transfusion adds iron to the body, and because the body has no natural way to remove excess iron, that iron accumulates in organs like the heart, liver, and endocrine glands over time. Left unmanaged, this iron overload is one of the more serious long-term risks of the condition.

That's where chelation therapy comes in — medication that helps the body remove excess iron before it causes organ damage. Depending on the specific medication, this can mean a daily pill or an injection delivered under the skin, and adherence to this routine is described by clinicians as one of the most important factors in long-term health outcomes. It's also, understandably, one of the harder parts of the routine to stay consistent with over months and years — which is exactly why many patients say having a stable daily habit (same time, same place, tied to something else you already do) makes more difference than willpower alone.

(Reviewer note: keep this section general — avoid naming specific chelation drugs or dosing schedules, since that crosses into treatment-specific guidance.)

Energy, Fatigue, and Planning Around Them

Even with a consistent transfusion schedule, energy levels for many people with thalassemia major follow a predictable rhythm: higher in the days right after a transfusion, gradually lower as the next one approaches. This isn't a sign that something's going wrong — it's a known pattern that many patients learn to plan around rather than fight. Scheduling demanding tasks, travel, or big social commitments earlier in the transfusion cycle, and building in more rest as the next one approaches, is a strategy many patients describe using instinctively once they recognize the pattern.

School, Work, and Everyday Responsibilities

A thalassemia major diagnosis does not mean school or a career is off the table — plenty of people manage both while living with the condition. What it usually does mean is a bit more communication and planning than the average student or employee needs:

• Letting a school or employer know about the recurring transfusion schedule, so absences are expected rather than a surprise each time
• Building in flexibility around the days immediately following treatment, when fatigue tends to be more noticeable
• Having a plan for sick days or infections, since the immune considerations around transfusion and, in some cases, spleen removal, mean illnesses may need closer attention than they would otherwise

None of this has to mean under-performing at school or work — it usually just means the schedule looks a little different than a typical nine-to-five, and that's worth normalizing rather than hiding.

Travel and Life Outside the Regular Schedule

Travel is absolutely possible with thalassemia major, but it takes more coordination than it does for most people. Clinical guidance for patients recommends coordinating travel plans with the transfusion schedule in advance, rather than trying to receive a transfusion somewhere unfamiliar, particularly in places where blood supply safety standards may differ. For anyone who has had a splenectomy, carrying antibiotics while traveling is also a commonly recommended precaution, in case of fever or infection while away from a regular care team.

None of this rules out travel, study abroad, or relocating for work — it just means those plans usually start with a phone call to your hematology team, not an afterthought.

The Emotional Side of a Lifelong Condition

It's worth naming directly: managing a chronic, lifelong condition that requires this much ongoing coordination is emotionally demanding, not just logistically demanding. Feeling frustrated by the schedule, tired of the routine, or occasionally wanting a break from all of it is an extremely common experience among people managing thalassemia major — not a sign of failing to cope well. Many patients describe cycles of adjusting to the routine, feeling stable for a while, and then needing to re-adjust again after a life change like starting college, a new job, or a relationship.

This is a big enough topic that it deserves its own space — we go into coping strategies and mental health support in more depth separately.

Building a Support System

One consistent theme across patient accounts and clinical literature is that people managing thalassemia major do better, by their own account and by measurable health outcomes, when they're not managing it entirely alone. That support can look like:

• A stable, ongoing relationship with one hematology team, rather than piecing care together from different providers each time
• Connection with organizations built specifically around thalassemia, which can offer both practical guidance and a sense of shared experience
• Family, friends, or a partner who understand the schedule well enough that it doesn't need to be re-explained every time

If you're newly navigating this, know that there is a well-established, decades-old community and body of medical support built specifically around this condition — you are not starting from zero.

---

FAQ

How often do people with thalassemia major need transfusions? Typically every two to four weeks, though the exact interval depends on individual factors your hematologist will determine.

Can someone with thalassemia major live a normal life? Yes, with modern transfusion and chelation care, many people with thalassemia major attend school, build careers, travel, and live well into adulthood — though it does require ongoing medical coordination.

Is chelation therapy done every day? Often, yes, depending on the specific medication prescribed — some are taken daily by mouth, others are delivered differently. Your hematologist will determine the right regimen for you.

What is the life expectancy for thalassemia major? Outcomes have improved substantially over recent decades with modern transfusion and chelation care, though individual outlook depends on factors like access to consistent treatment and how well iron overload is managed. (Reviewer note: consider linking to the dedicated life-expectancy post, scheduled for Week 8, rather than citing a specific number here.)

Can people with thalassemia major work full-time or attend school normally? Generally yes, with some planning around the transfusion schedule and recovery days — many people describe this becoming routine over time rather than a constant disruption.

---

This article is for general information and is not a substitute for professional medical advice. Treatment schedules, chelation regimens, and care decisions should always be made with your hematology team, based on your specific health status.

Reviewer flag: ⚠️ Recommend hematologist review before publishing — specifically the transfusion frequency range, the general chelation description (confirm no drug-specific dosing has crept in), and the life expectancy FAQ answer.

---

Sources consulted

• CDC — "Treatment of Thalassemia" (cdc.gov)
• Cooley's Anemia Foundation — thalassemia.org
• City of Hope — "Thalassemia Treatment: Transfusions, Chelation Therapy & More"
• NCBI Bookshelf — "General Health Care and Lifestyle in Thalassaemia," Guidelines for the Clinical Management of Thalassaemia
• Hematology-Oncology Associates of CNY — "Treatment of Thalassemias"

Thalassemia Diagnosis: Tests, Blood Work & What Results Mean

 If you're reading this, there's a good chance a blood test just came back with something unexpected — a low MCV, a note about your red blood cells, or a doctor who mentioned the word "thalassemia" and moved on before you could really ask what it meant. That gap, between hearing the word and understanding what's actually being tested, is where a lot of anxiety lives. This is meant to close that gap.

Thalassemia is rarely diagnosed with a single test. It's usually a sequence — one result prompting the next — and knowing the order helps the whole process feel less like a black box.

Why a Routine Blood Test Is Often Where This Starts

Most people first encounter thalassemia not because they went looking for it, but because it showed up as a side finding. A pre-marital screening, a prenatal visit, a routine physical, or an unrelated illness can all trigger a standard blood test that flags something worth a second look. A complete blood count is typically the first test ordered, since it measures hemoglobin levels and the number and appearance of red blood cells — and people with thalassemia generally have fewer healthy red cells and lower hemoglobin than expected.

The Complete Blood Count (CBC): The First Clue

The CBC is the test almost everyone has had at some point — it's part of routine checkups and pre-op screening. For thalassemia, the numbers that matter most aren't just your hemoglobin level, but the size and shape of your red blood cells.

What Is MCV (Mean Corpuscular Volume)?

MCV measures the average size of your red blood cells. In thalassemia, red blood cells are typically smaller than normal — a pattern doctors call "microcytic." Thalassemia is generally suspected when microcytic anemia shows up alongside a normal or elevated ferritin (iron storage) level, since that combination points away from simple iron deficiency.

Why a Low MCV Doesn't Automatically Mean Thalassemia

This is worth repeating clearly: a low MCV is a prompt for more testing, not a diagnosis on its own. Clinical guidance recommends following up a low MCV with a hemoglobin electrophoresis test, and doing the same for people from backgrounds where thalassemia is more common, including Mediterranean, Middle Eastern, African, West Indian, and Southeast Asian populations. If you're in Sri Lanka, where thalassemia carrier rates are relatively high, this is exactly the kind of result a doctor is likely to follow up on.

Hemoglobin Electrophoresis and HPLC: Confirming What Kind

If the CBC raises a flag, the next step usually looks directly at the hemoglobin itself, rather than just the cells carrying it.

What These Tests Actually Measure

Hemoglobin electrophoresis and high-performance liquid chromatography (HPLC) separate out the different types of hemoglobin in your blood, measuring the proportions of hemoglobin A, A2, F, and other variants. These are considered the most reliable methods available for confirming a hemoglobin disorder.

Making Sense of HbA, HbA2, and HbF

You don't need to memorize hemoglobin biochemistry to understand your results — you mainly need to know what a pattern shift signals:

• HbA is the main, "typical" adult hemoglobin.
• HbA2 and HbF are minor components in healthy adults, but their proportions often shift in thalassemia.

In beta-thalassemia specifically, the classic pattern is an increase in HbA2, sometimes along with an increase in HbF. A report showing elevated HbA2 alongside a low MCV is one of the more recognizable fingerprints of beta-thalassemia trait — but exact cutoff values vary somewhat by lab and population, so this is a conversation for your hematologist rather than a comparison against a generic number online.

The Mentzer Index: A Quick Screening Clue, Not a Diagnosis

You may come across the term "Mentzer index" if you've searched your own lab results. It's a simple ratio — MCV divided by red blood cell count — that labs sometimes use as a fast screening clue to help separate thalassemia trait from iron deficiency anemia, since the two can look similar on a basic CBC.

It's a useful screening tool, but it isn't a confirmed diagnosis on its own, and it's not something to calculate yourself as a substitute for your care team's interpretation of the full picture.

Genetic Testing: When It's Needed and What It Confirms

Electrophoresis and HPLC can strongly suggest thalassemia, but they don't always tell the whole story — especially for alpha-thalassemia, or when results sit in a borderline range. Genetic testing is often needed to confirm a diagnosis definitively. This matters most for:

• Family planning and carrier confirmation, especially before pregnancy
• Distinguishing between similar-looking hemoglobin variants
• Confirming a diagnosis in newborns or very young children, whose hemoglobin patterns are still shifting naturally in the first months of life

If you want the fuller picture on what genetic testing looks like before pregnancy specifically, [carrier screening before marriage or pregnancy] (link pending) walks through that process in more detail.

Telling Thalassemia Apart From Iron Deficiency Anemia

This distinction comes up constantly, because both conditions cause small, pale red blood cells, and both are common. The key differentiator is iron status: since thalassemia can look very similar to iron deficiency anemia on a basic CBC, doctors typically order a ferritin test to tell them apart. Low ferritin points toward iron deficiency; normal or high ferritin alongside microcytic anemia points more toward thalassemia.

This is exactly why iron supplements should never be started based on a low MCV alone — if the underlying cause is thalassemia rather than iron deficiency, iron supplementation isn't just unhelpful, it can contribute to iron overload over time. That decision should always sit with your doctor, based on your full test panel.

What Typically Happens After a Diagnosis

A confirmed thalassemia trait diagnosis, for most people, doesn't require ongoing treatment — it's information, not an illness in the day-to-day sense. A thalassemia major or intermedia diagnosis leads to a longer conversation with a hematologist about monitoring and, where relevant, treatment planning. Either way, the diagnostic pathway is designed to answer three questions in order: is this thalassemia, what type, and what does that mean for you and your family going forward.

---

FAQ

How is thalassemia diagnosed? Usually starting with a complete blood count that shows small, pale red blood cells, followed by hemoglobin electrophoresis or HPLC to identify the specific hemoglobin pattern, with genetic testing used to confirm the diagnosis when needed.

What blood test shows thalassemia? A CBC can raise suspicion through a low MCV, but hemoglobin electrophoresis or HPLC is the test that identifies the hemoglobin pattern associated with thalassemia.

What is a normal MCV level? Reference ranges vary slightly by lab, so ask your provider to interpret your specific result rather than comparing it to a general online range. (Reviewer note: insert a lab-verified reference range here before publishing.)

Can thalassemia be mistaken for iron deficiency anemia? Yes — both cause microcytic anemia, which is why a ferritin (iron) test is usually run alongside the CBC to tell them apart.

Is genetic testing necessary to confirm thalassemia? It's not always required, but it becomes important for confirming carrier status before pregnancy, distinguishing between similar hemoglobin variants, or clarifying a borderline result.

---

This article is for general information and is not a substitute for professional medical advice. If you or a family member have received an abnormal blood test result, please discuss the full results with your doctor or a hematologist, who can interpret your specific values in context.

Reviewer flag: ⚠️ Recommend hematologist review before publishing — specifically to verify reference ranges (MCV, HbA2 thresholds, Mentzer index cutoff) and confirm the iron-supplementation caution is phrased safely and accurately.

---

Sources consulted

• NHLBI, NIH — "Thalassemia: Diagnosis" (nhlbi.nih.gov)
• American Academy of Family Physicians — "Alpha- and Beta-thalassemia: Rapid Evidence Review" (aafp.org)
• NCBI Bookshelf / StatPearls — "Laboratory Evaluation of Alpha Thalassemia" and "Laboratory Evaluation of Beta Thalassemia"
• NCBI Bookshelf / GeneReviews — "Beta-Thalassemia"
• UCSF Northern California Comprehensive Thalassemia Center — "Symptoms & Diagnosis"

How Vitamin A can Reduce Scarring in Blood Vessels

While scarring is a natural part of any healing process, scar formation within our blood vessels can be deadly. A team of US researchers has developed a new biodegradable material with built-in vitamin A which has been shown to reduce scarring in blood vessels.

"When injury occurs, cells proliferate and migrate into the blood vessel, creating scar-like tissue. It can create blockages that impair blood flow," said lead researcher Guillermo Ameer from the Northwestern University.

The soft elastic material can be used to treat injured vessels or be used to make medical devices such as stents and prosthetic vascular grafts. Early tests have shown that the material can reduce cell migration - a major contributor to the scarring process - by 57%.

"In his new work, vitamin A is integrated into the material, harnessing the beneficial properties of vitamin A and allowing for its broader application in medical devices," the authors noted in a paper published in the ACS Biomaterials Science and Engineering.

This new advanced material brings together two major advantages. Its antioxidant component can reduce the oxidative stress that leads to chronic inflammation.

Vitamin A, which is released as the material degrades, can prevent or reduce scarring.

It can potentially also be used outside the body such as for wound-healing bandages for diabetic patients.

Because the new material releases vitamin A as it degrades, the potential for toxic build up is much lower.

Ameer's team can also control how quickly the material degrades - and thus releases the vitamin A - depending on how the material is produced in the laboratory.

The team now plans to explore the material's potential for additional applications. Vitamin A is already widely known for its anti-aging properties and topical antioxidants can be used to combat cell damage or improve wound healing.

Source: IANS

Encapsulated Human Islet Cells can Normalize Blood Sugar Read more: Encapsulated Human Islet Cells can Normalize Blood Sugar

Scientists studying a mouse model of diabetes have implanted encapsulated insulin-producing cells derived from human stem cells and maintained long-term control of blood sugar -- without administering immunosuppressant drugs.

 The results of the multi-institutional effort are published in Nature Medicine. People with type 1 diabetes have an overactive immune system that destroys the insulin-producing islet cells in the pancreas. Lacking that hormone, the body fails to convert sugars to usable energy, and glucose rises to harmful levels in the blood without daily insulin injections.

Islet cells have been successfully transplanted to treat type 1 diabetes, but those patients must take immunosuppressant drugs to keep their immune system from destroying the transplanted cells. Previous research had shown that rodent islet cells could normalize blood sugar levels in animal models without immunosuppression if the cells were encased in hydrogel capsules.

The semi-porous capsules allow insulin to escape into the blood, while preventing the host's immune system from attacking the foreign cells. Larger capsules, about 1.5 millimeters across, even seemed able to avoid the buildup of scar tissue, which can choke off the cells' supply of oxygen and nutrients. The new study, a collaboration led by scientists at the Massachusetts Institute of Technology and Boston Children's Hospital, used islet cells derived from human stem cells and capsules made of chemically-tweaked gel that are even more resistant to the build-up of scar tissue.

Dr. Jose Oberholzer, chief of transplantation surgery and director of cell and pancreas transplantation at the University of Illinois Hospital & Health Sciences System, professor of bioengineering at the University of Illinois at Chicago, and an author on the paper, tested several varieties of chemically-modified alginate hydrogel spheres -- in various sizes -- to see if any excelled at resisting scar-tissue formation.

Oberholzer and his coworkersat the University of Illinois at Chicago first tested the spheres to ensure they would allow the islet cells to function inside a host. Using a special microfluidic device developed at UIC under a grant from the National Institute of Diabetes and Digestive and Kidney Diseases, they delivered minute amounts of glucose into tiny wells containing encapsulated islet cells and measured the amount of insulin that seeped out.

They implanted spheres that showed promise into rodents and non-human primates to look for the development of scar tissue. They found (and reported in the journal Nature Biotechnology) that 1.5-millimeter spheres of triazole-thiomorphine dioxide (TMTD) alginate were best at allowing allowing insulin to escape while resisting immune response and the buildup of scar tissue. When implanted into a mouse model of diabetes, TMTD-alginate spheres containing human islet cells were able to maintain proper blood glucose control for 174 days -- decades, in terms relative to the human lifespan.

"When we stopped the experiment and took the spheres out, they were virtually free of scar tissue," Oberholzer said. "While this is a very promising step towards an eventual cure for diabetes, a lot more testing is needed to ensure that the islet cells don't de-differentiate back toward their stem-cell states or become cancerous," said Oberholzer. If the cells did become cancerous, he said, they could easily break through the spheres.

Oberholzer also cautioned that a cure for human diabetes would require scientists to develop techniques to grow large numbers of human islet cells from stem cells -- a worthy goal. "In the United States, there are 30 million cases of type 2 diabetes and about 2 million patients with type 1 diabetes who could potentially benefit from such a procedure," he said. "But we need to grow billions of islet cells."

Source: Eurekalert

Anemia: One-minute point-of-care test shows promise in new study

A simple point-of-care testing device for anemia could provide more rapid diagnosis of the common blood disorder and allow inexpensive at-home self-monitoring of persons with chronic forms of the disease.

A simple point-of-care testing device for anemia could provide more rapid diagnosis of the common blood disorder and allow inexpensive at-home self-monitoring of persons with chronic forms of the disease.

 Erika Tyburski is shown with a prototype device for point-of-care testing of anemia. The device could enable more rapid diagnosis of the common blood disorder and allow inexpensive at-home self-monitoring of persons with chronic forms of the disease.

 The disposable self-testing device analyzes a single droplet of blood using a chemical reagent that produces visible color changes corresponding to different levels of anemia. The basic test produces results in about 60 seconds and requires no electrical power. A companion smartphone application can automatically correlate the visual results to specific blood hemoglobin levels.

By allowing rapid diagnosis and more convenient monitoring of patients with chronic anemia, the device could help patients receive treatment before the disease becomes severe, potentially heading off emergency room visits and hospitalizations. Anemia, which affects two billion people worldwide, is now diagnosed and monitored using blood tests done with costly test equipment maintained in hospitals, clinics or commercial laboratories.

Because of its simplicity and ability to deliver results without electricity, the device could also be used in resource-poor nations.
A paper describing the device and comparing its sensitivity to gold-standard anemia testing was published August 30 in The Journal of Clinical Investigation. Development of the test has been supported by the FDA-funded Atlantic Pediatric Device Consortium, the Georgia Research Alliance, Children's Healthcare of Atlanta, the Georgia Center of Innovation for Manufacturing and the Global Center for Medical Innovation.

"Our goal is to get this device into patients' hands so they can diagnose and monitor anemia themselves," said Dr. Wilbur Lam, senior author of the paper and a physician in the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta and the Department of Pediatrics at the Emory University School of Medicine. "Patients could use this device in a way that's very similar to how diabetics use glucose-monitoring devices, but this will be even simpler because this is a visual-based test that doesn't require an additional electrical device to analyze the results."
The test device was developed in a collaboration of Emory University, Children's Healthcare of Atlanta and the Georgia Institute of Technology -- all based in Atlanta. It grew out of a 2011 undergraduate senior design project in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. In 2013, it was among the winners of Georgia Tech's InVenture Prize, an innovation competition for undergraduate students, and won first place in the Ideas to SERVE Competition in Georgia Tech's Scheller College of Business.

Using a two-piece prototype device, the test works this way: A patient sticks a finger with a lance similar to those used by diabetics to produce a droplet of blood. The device's cap, a small vial, is then touched to the droplet, drawing in a precise amount of blood using capillary action. The cap containing the blood sample is then placed onto the body of the clear plastic test kit, which contains the chemical reagent. After the cap is closed, the device is briefly shaken to mix the blood and reagent.

"When the capillary is filled, we have a very precise volume of blood, about five microliters, which is less than a droplet -- much less than what is required by other anemia tests," explained Erika Tyburski, the paper's first author and leader of the undergraduate team that developed the device.
Blood hemoglobin then serves as a catalyst for a reduction-oxidation reaction that takes place in the device. After about 45 seconds, the reaction is complete and the patient sees a color ranging from green-blue to red, indicating the degree of anemia.

A label on the device helps with interpretation of the color, or the device could be photographed with a smartphone running an application written by Georgia Tech undergraduate student Alex Weiss and graduate student William Stoy. The app automatically correlates the color to a specific hemoglobin level, and could one day be used to report the data to a physician.

To evaluate sensitivity and specificity of the device, Tyburski studied blood taken from 238 patients, some of them children at Children's Healthcare of Atlanta and the others adults at Emory University's Winship Cancer Institute. Each blood sample was tested four times using the device, and the results were compared to reports provided by conventional hematology analyzers.

The work showed that the results of the one-minute test were consistent with those of the conventional analysis. The smartphone app produced the best results for measuring severe anemia.
"The test doesn't require a skilled technician or a draw of venous blood and you see the results immediately," said Lam, who is also an assistant professor in the Coulter Department of Biomedical Engineering. "We think this is an empowering system, both for the general public and for our patients."

Tyburski and Lam have teamed up with two other partners and worked with Emory's Office of Technology Transfer to launch a startup company, Sanguina, to commercialize the test, which will be known as AnemoCheck™. The test ultimately will require approval from the FDA. The team also plans to study how the test may be applied to specific diseases, such as sickle cell anemia -- which is common in Georgia.

The device could be on pharmacy shelves sometime in 2016, where it might help people like Tyburski, who has suffered mild anemia most of her life. "If I'd had this when I was kid, I could have avoided some trips to the emergency room when I passed out in gym class," she said.
About a third of the population is at risk for anemia, which can cause neurocognitive deficits in children, organ failure and less serious effects such as chronic fatigue. Women, children, the elderly and those with chronic conditions such as kidney disease are more likely to suffer from anemia.

---

Story Source:
The above story is based on materials provided by Georgia Institute of Technology. The original article was written by John Toon. Note: Materials may be edited for content and length.

Medical leap gives hope to blood disorder sufferers

Gene therapy for the blood disorder beta-thalassemia will be carried out in Thailand for the first time by the end of this year.

A team of doctors at Ramathibodi Hospital is studying the gene therapy technology alongside experts in Paris under a collaboration programme between the Mahidol University led by Prof Suthat Fucharoen and French-American researcher Philippe Leboulch of Harvard Medical School and the University of Paris.
The Thai doctors expect to return to Thailand to conduct a trial around December, said Dr Suradej Hongeng, of Ramathibodi Hospital's department of pediatrics.
The collaboration came about after the world's first successful treatment of beta-thalassemia with gene therapy.
A 21-year-old Frenchman treated with the therapy in 2007 now no longer has the need for blood transfusions. He previously had required transfusions every month since birth.
The successful treatment was published in the journal Nature last September.
Beta-thalassemia is caused when a patient cannot produce enough of the beta-globin component of haemoglobin, the protein used by red blood cells to carry oxygen around the body. This can cause life-threatening anaemia, leading to severe damage of the body's major organs.
Gene therapy is generally the insertion, alteration or removal of genes within a patient's cells and biological tissues to treat disease.
"This success justifies the hopes placed in the use of gene therapy to treat blood diseases," said Dr Suradej, a haematology specialist.
"It is also the first time an effective technology has been developed to improve the quality of life for people with thalassemia."
An estimated 20 million Thais are carriers of thalassemia. It is one of the world's most common genetic disorders, putting an enormous financial strain on Thailand and countries located in the "Thalassemia Belt", which stretches from the Mediterranean through the Middle East and Central Asia to Southeast Asia.
About three in 800 children born in Thailand are affected by the severest form of the disorder, beta-thalassemia, requiring regular blood transfusions.
However, blood transfusions carry the risk of contracting HIV and hepatitis B and C from donors, or iron overloading.
The only known cure for the condition is through a bone marrow transplant.
However, this process is dangerous and it can be very difficult to find a matching bone marrow donor, Dr Suradej said.
He hoped the gene therapy for thalassemia treatment would eliminate the problems posed by bone marrow transplants, as well as lead doctors to adapt the technology to treat the symptoms of beta-thalassemia, such as as neurological problems and muscle disabilities.

Researchers report gene therapy strategy that improves Beta Thalassemia in mice model

Researchers at Nationwide Children's Hospital report a gene therapy strategy that improves the condition of a mouse model of an inherited blood disorder, Beta Thalassemia. The gene correction involves using unfertilized eggs from afflicted mice to produce a batch of embryonic stem cell lines. Some of these stem cell lines do not inherit the disease gene and can thus be used for transplantation-based treatments of the same mice. Findings could hold promise for a new treatment strategy for autosomal dominant diseases like certain forms of Beta Thalassemia, tuberous sclerosis or Huntington's disease.
Embryonic stem cells have the potential to produce unlimited quantities of any cell type and are therefore being explored as a new therapeutic option for many diseases. Unfertilized eggs can be cultured to form embryonic stem cells, so-called parthenogenetic embryonic stem cells.
"Parthenogenetic embryonic stem cells can differentiate into multiple tissue types as do stem cells from fertilized embryos," said K. John McLaughlin, PhD, principal investigator in the Center for Molecular and Human Genetics at The Research Institute at Nationwide Children's Hospital. Previously, the group demonstrated that blood cells derived from parthenogenetic cells could provide healthy, long-term blood replacement in mice.
"Advantages of parthenogenetic stem cells are not only that fertilization is not needed, but also that the recipient's immune system may potentially not view them as foreign, minimizing rejection problems. Furthermore, since parthenogenetic embryonic stem cells are derived from reproductive cells which contain only a single set of the genetic information instead of the double set present in body cells, they may not contain certain abnormal genes present in the other copy," said Dr. McLaughlin also one of the study authors.

A single copy of an abnormal gene inherited from one parent can cause so-called autosomal dominant diseases such as tuberous sclerosis or Huntington's disease. The affected person has one defective and one normal copy of the gene, but the abnormal gene overrides the normal gene, causing disease. In normal sexual reproduction, each parent provides one gene copy to offspring via their reproductive cells. Therefore, the reproductive cells of a patient with an autosomal dominant disease could either pass along a defective copy or a normal copy.
"As the donor patient has one defective gene copy and one normal, and only one copy is used for normal reproduction, we can select egg-cell-derived embryonic stem cells with two normal copies," said Dr. McLaughlin. "These single-parent/patient-derived embryonic stem cells can theoretically be used for correction of a diverse number of diseases that occur when one copy of the gene is abnormal," said Dr. McLaughlin.
To test this theory, Dr. McLaughlin and colleagues from the University of Pennsylvania, University of North Carolina and University of Minnesota, examined whether parthenogenetic embryonic stem cells could be used for tissue repair in a mouse model of thalassemia intermedia. Thalassemia intermedia is an inherited blood disorder in which the body lacks sufficient normal hemoglobin, leading to excessive destruction of red blood cells and anemia. They used a mouse model in which one defective gene copy causes anemia.
Using approaches developed from a previous study done by this group, Nationwide Children's Research Fellow Sigrid Eckardt, PhD, derived embryonic stem cells from the unfertilized eggs of female mice with the disease, and identified those stem cell lines that contained only the "healthy" hemoglobin genes. These "genetically clean" embryonic stem cell lines were converted into cells that were transplanted into afflicted mice that were carriers of the disease causing gene. Blood samples drawn five weeks after transplantation revealed that the delivered cells were present in the recipients' blood. Their red blood cells were also corrected to a size similar to normal mice and red blood cell count, hematocrit and hemoglobin levels became normal.
"Overall, we observed long-term improvement of thalassemia in this model," said Dr. Eckardt. "Our findings suggest that using reproductive cells to generate embryonic stem cells that are 'disease-free' may be a solution for genetic diseases involving large, complex or poorly identified deletions in the genome or that are not treatable by current gene therapy approaches." Dr. McLaughlin says that this approach also contrasts with typical gene therapy approaches in that it requires no engineering of the genome, which is currently difficult to achieve in human embryonic and embryonic-like (IPS) stem cells.

Source: Nationwide Children's Hospital

Beta-Thalassemia: Gene Therapy Breakthrough

Italian scientists pioneering a new gene transfer treatment for the blood disorder β-thalassemia have successfully completed preclinical trials, claiming they can correct the lack of beta-globin (β-globin) in patients' blood cells which causes the disease. The research, published in EMBO Molecular Medicine, reveals how gene therapy may represent a safe alternative to current cures that are limited to a minority of patients.

The disorder β-thalassemia, also known as Cooley's anemia, is caused when a patient cannot produce enough of the β-globin component of haemoglobin, the protein used by red blood cells to carry oxygen around the body. The lack of β-globin causes life threatening anemia, leading to severe damage of the body's major organs. The condition is most commonly found in Mediterranean, Middle Eastern and Asian populations.

"Currently treatments are limited to lifelong regular blood transfusions, and iron chelation to prevent fatal iron overload. The alternative is bone marrow transplantation, an option open to less than 25% of patients," said Dr Giuliana Ferrari from the San Raffaele Telethon Institute for Gene Therapy in Milan. "Our research has focused on gene therapy: by transplanting genetically corrected stem cells we can restore haemoglobin production and overcome the disorder."

Diseases of the blood are good targets for gene therapy because it is possible to harvest stem cells from the patient's bone marrow. The team developed a tool to deliver the correct gene for ß-globin into these harvested cells, a viral vector they called GLOBE.

The cells can then be genetically modified with GLOBE to restore hemoglobin production before being re-administered back into the patient via intravenous injections. The important focus of this work was not only to show that GLOBE can restore haemoglobin production in human cells, but that this genetic transfer-based approach does not impair the biological features of the cells and is not associated with any intrinsic risk for the human genome.

This research is not only crucial for developing a cure for one disease, but as Dr David Williams from the Harvard Medical School says, it may advance the entire discipline of gene therapy research

"This work represents the kind of translational studies that are required to move human investigations forward but are often difficult to fund and publish," said Williams. "Considering the inherent difficulties accompanying human research, studies like those reported in EMBO Molecular Medicine are extremely important for moving the field forward." As the Milan based team can now correct the defective production of beta-globin in patients' blood cells the next step will be to place the corrected cells back into the patient, a step which has already proven successful in mice.

Successful gene therapies are the results of very long studies and our research represents the most comprehensive pre-clinical analysis ever performed on cells derived from thalassemic patients" concluded Ferrari. "We believe this study paves the way forward for the clinical use of stem cells genetically corrected using the GLOBE vector."

Source:
Ben Norman
Wiley-Blackwell

Researchers discover genetic explanation for non-diabetic kidney disease in African-Americans

Variants in the APOL1 gene help explain high rates of renal disease in individuals of recent African ancestry; authors speculate that these variants originally evolved as a survival mechanism against parasitic disease in Africa
Kidney disease is a growing public health problem, with approximately half a million individuals in the United States requiring dialysis treatments to replace the function of their failed kidneys. The problem is particularly acute among African-Americans, whose rates of kidney disease are four times higher than those of European Americans.

As reported online this month by the journal Science, collaborating research groups found that patients with focal segmental glomerulosclerosis (FSGS) and hypertension-attributed end-stage kidney disease (H-ESKD) harbored variants in the APOL1 gene that changed the ApoL1 protein sequence. These variants are commonly found in individuals of recent African ancestry.

Furthermore, in a twist of evolutionary medicine, the disease-causing variants may have protected Africans against a lethal parasite, explaining why these genetic variants are so common in the population today.
Researchers at Wake Forest University Baptist Medical Center contributed to and participated in this scientific team, led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and the Universite Libre de Bruxelles. Together, they discovered a genetic explanation - with evolutionary roots - for the higher incidence of non-diabetic kidney disease in African-Americans.

"We found that the APOL1 risk genes for renal disease occur in more than 30 percent of African-American chromosomes," explained co-senior author Martin Pollak, M.D., chief of nephrology at BIDMC and associate professor of medicine at Harvard Medical School. "In fact, the increased risk of kidney disease in individuals who inherited two copies of these variant forms of APOL1 is reported to be approximately 10-fold."
FSGS is a form of injury to the kidney's filtering system, which causes proteins to be lost into the urine and gradually reduces kidney function. ESKD, or end-stage kidney disease, is defined by kidney failure that has progressed to the point that the patient requires dialysis or kidney transplantation.

It has long been thought that high blood pressure is a common cause of end stage kidney disease in African-Americans," said study co-researcher Barry Freedman, M.D., John H. Felts III Professor and chief of the section on nephrology at WFUBMC. "However, the strong association between variants in the APOL1 gene and hypertension-attributed kidney disease suggested that this kidney disease truly resides in the spectrum of FSGS and is not due to hypertension as was initially believed."
More than 2,000 study participants from the southeastern United States were recruited to the study by WFUBMC.

Last year, Freedman led a team of WFUBMC researchers who found that genetic variation near the MYH9 gene on chromosome 22 was also associated with increased risk of hypertension-attributed kidney disease in African-Americans. However, because genome analyses had shown a strong signal of natural selection in the region containing both the MYH9 and APOL1 genes, the authors reasoned that the location of the disease-causing genetic variants was in a broader region. They also predicted that the frequency of these variants would be markedly different between European-Americans and Africans.

Using data from the 1000 Genomes Project DNA data bank, the authors identified candidate genetic variants and tested for their presence in DNA sample sets. They found that two APOL1 variants - dubbed G1 and G2 - were associated with an increased risk of both FSGS and hypertension-attributed ESKD in African-Americans.
"G1 and G2 both changed the coding sequence of APOL1," Pollak explained. "Further analyses revealed that these very same genetic variants [G1 and G2] conferred human immunity against the parasite responsible for sleeping sickness."

African sleeping sickness is caused by an African trypanosome parasite, which is transmitted by the tsetse fly. The disease, which produces severe nervous system disorders that can ultimately lead to brain damage, coma and death, is estimated to affect tens of thousands of people, but is not found outside of Africa.
The APOL1 protein circulates in the blood and helps defend against trypanosomes, a finding initially discovered by co-senior author Etienne Pays, Ph.D., of the Universite Libre de Bruxelles, in Belgium. In the current study, Pays' laboratory found that the plasma from patients harboring the G1 and G2 variants inactivated the trypanosomes that cause the deadliest forms of African Sleeping Sickness, as did the APOL1 protein with these same variants inserted.

"We were excited that our findings appeared to relate kidney disease in the United States with human evolution and parasite infection in Africa," Pollak said. "While there are many details that remain to be clarified in future studies, we do know that sickle-cell disease is a well-established precedent for this model, in which one copy of the mutation confers protection against a parasitic infection but two copies of the mutation can cause severe disease." Pollak explained that, when present in a single copy, certain hemoglobin mutations protect against malaria. But two copies cause sickle cell disease or thalassemia, severe red-blood cell diseases.
"It appears that we may have found a similar situation in APOL1," Pollack added. "Consequently, while these genetic variants protect against sleeping sickness, they also greatly increase a person's susceptibility to kidney disease. We hope that these new findings will not only lead us to a better understanding of the underlying mechanisms leading to kidney failure, but will also help us develop new ways to treat trypanosome infection and kidney disease."

Dispelling the stigma attached to blood disorder

Prakash Jaga, 23, from Sherwood was diagnosed with thalassaemia when he was a baby.
Thalassaemia is a genetic disorder of the blood that causes a form of anaemia, decreasing the number of red blood cells. The condition is hereditary and mainly affects those of Mediterranean descent and is also common in the Arabian Peninsula, Iran, Pakistan and southern China.
In South Africa, it is found mainly in those of Indian descent as well as in the Greek, Italian and Portuguese communities.
There are approximately 250 to 300 Indians in the country who have the blood condition.
There are two types of thalassaemia - minor, a less severe form where patients present a mild form of anaemia and major, a chronic condition requiring lifelong medical intervention.
The disorder is inherited from both parents who are carriers of thalassaemia minor. Parents who are carriers have a one-in-four chance of passing on the condition to their children.
Treatment of the condition requires a lifelong cycle of blood transfusion every three to four weeks for the rest of the patient's life.
Dr Yasmin Goga, a paediatric haematology consultant, said the condition presented itself between the ages of six months to a year. She said without treatment it would eventually lead to car-diac failure and death within the first two years of an affected child's life.
Last week Saturday marked World Thalassaemia Day. As a result, Jaga and the South African Thalassaemia Association are aiming to raise more awareness about the condition.
Jaga said when he told people about it, they assumed that, because it was a blood disorder, it was related to Aids.
"A lot of people are ignorant. They hear about it and then take a step back from me because they think it's contagious. I have had women who have been out with me and when I tell them, they take a step back. They think it's something similar to Aids."
But Jaga said having the condition has not prevented him from living a normal, full life.
"You get used to living with it. Initially it is a shock for parents and it's hard for the child to get used to it because you are getting injected every three weeks with a drip.
"But you slowly adjust to it and you come to realise that, if you don't do it, you will die. Without the blood transfusion you become weak and oxygen stops running in your body and your organs will give up."
He said with the help of the association they were trying to educate people about the disorder.
Jaga, who works in administration for a travel company, said every three weeks he took a day off work to get his treatment done, saying some days were "good" while others were "tiring".
He said people needed to have a positive outlook on life. "There is a lot that you can do. If you are on the treatment, you can live a long and happy life. If people ask you about it, educate them."
With transfusions every week, thalassaemia patients suffer with iron overload which gets deposited in their liver and can eventually lead to cardiac failure. In an attempt to prevent this, the patient is injected five times a week.
However, because of the invasive manner of the injections a new drug was developed, which is taken orally. The South African Thalassaemia Association campaigned for the drug to be made available to South Africans in 2006.
Sunil Soni, chairperson of the association, said the core function of the group was to provide patients and extended families with support regarding the treatment of the disorder. He said the condition could cost approximately R300000 a year.
"The condition is very complicated, so we have the association to improve the quality of life for all living with it. There is not enough awareness about this condition."
Soni said the condition was sometimes misdiagnosed and presented as anaemia.
"There are many people who are carrying the gene but they don't know it. So our duty is to empower people so that they can make educated decisions about the future of their family."